Recent Updates
Recently added Catalysts
KRMD Positive Sentiment

KORU Medical Systems to Participate in Upcoming Investor Conferences

Wednesday, November 4, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: KORU Medical Systems announced participation in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum. Management will present at the event in November. The company develops large volume subcutaneous infusion solutions. This appearance aims to engage with investors regarding its medical technology platform.

Market Sentiment Analysis

POSITIVE FACTORS

  • KORU Medical is participating in a notable investor conference.
  • The company focuses on innovative infusion solutions.
  • Management's presentation may attract investor interest.

Full Press Release Details

MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced that the Company will participate in the following investor conference: Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum. Management is scheduled to present on Novembe

Frequently Asked Questions

Which conference will KORU attend?

KORU Medical will participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum.

When is the management presentation?

Management is scheduled to present on November, though the specific day is not stated in the text.

What is KORU Medical's focus?

The company focuses on development, manufacturing, and commercialization of large volume subcutaneous infusion solutions.

What is the company ticker?

KORU Medical Systems trades on the NASDAQ under the ticker symbol KRMD.

ShareAdd on Google
Tags: KRMD KORU Medical investor conference infusion solutions Canaccord Genuity
Last updated: Nov 4, 2026

Biotech snapshot

Cash runway
$8M liquidity · $0M/mo burn
Low dilution risk